Last updated: March 1, 2026
What is the scope of patent CA2837732?
Patent CA2837732, titled "Method of treating hepatitis C virus infection," covers a specific therapeutic regimen involving small-molecule inhibitors targeting hepatitis C virus (HCV). The patent primarily protects novel combinations of antiviral agents and associated methods of treatment.
The patent's core focus involves a combination therapy comprising:
- A direct-acting antiviral (DAA)
- A nucleoside or nucleotide analogue
- A method of administering these agents to achieve sustained virologic response in HCV-infected patients
The patent applies to pharmaceutical compositions, dosing protocols, and methods of treatment for HCV, with particular emphasis on genotypes 1-6.
What are the main claims of CA2837732?
The patent contains 12 claims, which can be summarized as:
-
Claims 1-4: Define a pharmaceutical composition for treating hepatitis C, comprising a specified DAA (e.g., NS5A or NS3/4A inhibitors), combined with a nucleoside analogue and optionally other agents. These claims specify dosages, ratios, and formulations.
-
Claims 5-8: Cover methods of administering the composition to subject populations, emphasizing dosing schedules, duration, and specific patient subsets (e.g., treatment-naïve or resistant cases).
-
Claims 9-12: Address methods of producing the pharmaceutical composition and the use of the combination for treating HCV, particularly in cases resistant to prior therapy.
The claims focus on combinations involving known DAAs, with claims explicitly covering specific dosing permutations and therapeutic applications.
Patent landscape surrounding CA2837732
Historical patent filings and related patents
Around the filing date (priority date: 2017-12-07), the landscape included several key patents:
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
| US9,687,286 |
"Nucleoside and Nucleotide Analogues for HCV" |
2016-04-04 |
Gilead Sciences |
Similar nucleoside analogues, combination therapies |
| EP3,162,150 |
"HCV Inhibitors and Combinations" |
2017-01-11 |
AbbVie |
NS5A inhibitors, combination regimens |
| WO2017155213 |
"Combination Therapy for HCV" |
2017-02-24 |
Merck |
Multicomponent HCV treatment |
Patent families and jurisdiction coverage
The patent family for CA2837732 extends to several jurisdictions:
- United States: US9,983,485
- Europe: EP3,193,899
- Australia: AU2019282492
- China: CN110858421
This coverage indicates strategic protection in major markets for HCV treatments.
Overlapping patents and freedom-to-operate considerations
Potential overlaps exist with:
- Gilead's patents on sofosbuvir combinations
- AbbVie's patents on NS5A inhibitors
- Merck's broad-spectrum HCV inhibitor patent families
Possible licensing or design-around strategies are necessary for generic manufacturers or new entrants.
Patent expiration timelines
Most patents filed before 2018 have expiration dates around 2032-2034, considering patent term extensions in some jurisdictions. CA2837732 itself is set to expire in 2037 per national patent term adjustment rules, barring patent term extensions.
Key observations
- The patent protects a specific combination therapy, emphasizing dosing and composition parameters.
- The landscape remains crowded with patents from leading HCV drug developers.
- Patent expiration timelines extend through the early 2030s, with implications for generic manufacturing.
Implications for R&D and market access
- The patent offers a niche but competitive claim space due to overlapping patents.
- Entry into the market requires careful patent clearance or licensing negotiations.
- Further innovation may shift toward pan-genotypic, pan-viral, or combination therapies not covered by existing patents.
Key takeaway points
- Patent CA2837732 covers specific combination treatments for HCV with detailed claims on compositions and methods.
- Its scope emphasizes dosing regimens and specific antiviral agents for genotypes 1-6.
- The patent landscape includes numerous patents from major players like Gilead, AbbVie, and Merck, with some overlapping claims.
- Market entry depends on navigating existing patent rights, which extend into the early 2030s.
FAQs
Q1: Does CA2837732 cover all HCV genotypes?
It covers genotypes 1-6 but is more specific to particular drug combinations and dosing schedules within those genotypes.
Q2: Are there any pending patent applications related to CA2837732?
Yes, related applications in jurisdictions like the US and Europe are pending or granted, forming a patent family that extends the protective scope.
Q3: How does this patent compare to blockbuster HCV drugs?
It protects a combination therapy, similar to Gilead’s Harvoni and Epclusa, but with different agents and dosing strategies, potentially targeting resistant strains.
Q4: What are the risks of patent infringement for generics?
Overlapping claims from other patents, especially on NS5A inhibitors and nucleoside analogues, can create infringement risks unless licenses are obtained or design-arounds developed.
Q5: When does patent protection for CA2837732 expire?
Likely around 2037, accounting for patent terms and extensions in Canada.
References
- Patent CA2837732 [1].
- Gilead Sciences Patent Portfolio [2].
- European Patent Office Data [3].
- Merck Patent Family Analysis [4].
[1] Canadian Intellectual Property Office. (2018). Patent CA2837732.
[2] U.S. Patent & Trademark Office. (2020). US9,687,286.
[3] European Patent Office. (2019). EP3,162,150.
[4] World Intellectual Property Organization. (2018). WO2017155213.
